CCEP’s Buyback Strategy: A Tactical Discount Play or a Smart Earnings Boost?

The event is clear: Coca-Cola Europacific Partners (CCEP) launched a coordinated €1 billion share buyback programme on February 17, 2026. The plan, to be executed across its Nasdaq and London listings, is expected to wrap up by late February 2027. The timing is no accident. The announcement came alongside the company's robust 2025 results, which included a 37% surge in after-tax profit to 1.98 billion euros. This wasn't just a routine capital return; it was a strong signal of confidence from management, framed as part of a broader commitment to shareholder value.

The immediate market reaction underscored the program's perceived importance. On the announcement day, CCEP's London-listed shares rose almost 3%. That pop suggests investors viewed the buyback as a bullish endorsement of the company's financial strength and future prospects, especially given the context of a year where revenue also grew and volume expanded.

The core of the tactical analysis now hinges on execution. The program's impact on valuation will depend heavily on the mechanics: the price paid for shares relative to recent volatility and the timing of purchases. A buyback executed at elevated levels could dilute the per-share value of the capital returned, while a disciplined, opportunistic approach could provide a more meaningful boost to earnings per share. The program's structure, involving Goldman Sachs as a riskless principal, aims to manage market impact, but the ultimate price paid remains the critical variable.

Execution Mechanics and Price Paid: A Tactical Review

The tactical setup now hinges on the actual price paid. The company is executing its €1 billion plan, and the recent weekly repurchase data reveals a clear pattern: CCEP is buying shares in a range, not chasing momentum at the peak. From March 10 to 16, the company made a series of daily purchases, acquiring 50,000 shares on US venues and 20,000 on London each day for four consecutive days. The price paid was consistent, with volume-weighted averages for US trades averaging $100–102 and London venue prices in the mid-70s. More specifically, the week's trades show prices from $99.44 to $103.05 on US venues and £74.20 to £77.00 on London. This isn't a scattergun approach; it's a disciplined, opportunistic buy.

Crucially, the current share price provides context for this range. As of March 19, CCEP's stock trades at €94.71. That figure is 14.5% below its 52-week high of €110.90. The buyback is therefore occurring in a zone that is a meaningful discount to recent peaks. Management is not paying a premium for its own stock; it is acting as a buyer of last resort in a slightly softer market.

The scale of the programme relative to the company's size adds weight to the move. A €1 billion buyback represents a significant reduction in shares outstanding if fully executed. For a company with a market cap in the tens of billions, this is a material capital return. The execution mechanics, managed through Goldman Sachs as a riskless principal, aim to minimize market impact. The real test is whether the average price paid-around $101 on US venues and £76 on London-provides a favorable return on capital for shareholders. Early evidence suggests the company is buying at a discount to its recent highs, which is a positive tactical setup.

Valuation and Risk/Reward Setup

The tactical math is straightforward. A €1 billion buyback is expected to be accretive to earnings per share, a critical metric for a stock with a growing dividend. The company's 2025 EPS was 4.26 euros, and reducing shares outstanding directly boosts that figure. The magnitude of that EPS accretion, however, hinges entirely on the average price paid. Early execution shows the company is buying at a discount to recent peaks, with weekly trades averaging $100–102 on US venues and GBP mid-70s on London. That's a favorable setup, as the current share price of €94.71 sits 14.5% below its 52-week high.

The primary risk is timing. While the current price is a discount, it is also near the top of the recent trading range. Buying shares now, even at a discount to the high, could be seen as opportunistic rather than value-driven. The real test is whether the average cost over the next 12 months stays meaningfully below the peak. The company's guidance for 7% operating profit growth in 2026 provides a solid earnings foundation, but the buyback's return depends on the capital allocation discipline.

The near-term catalyst is the weekly disclosure of repurchase volumes and prices. These reports, filed with regulators, will signal the company's commitment and reveal the actual average cost. A continuation of disciplined, range-bound buying would reinforce the tactical thesis. Any shift to aggressive purchases at the high end of the range would raise questions about the program's value. For now, the setup is balanced: a material capital return at a reasonable price, but the final verdict on its wisdom must wait for the full execution data.